AP2014008139A0 - Acrylamide compounds as histamine H3 receptor ligands - Google Patents
Acrylamide compounds as histamine H3 receptor ligandsInfo
- Publication number
- AP2014008139A0 AP2014008139A0 AP2014008139A AP2014008139A AP2014008139A0 AP 2014008139 A0 AP2014008139 A0 AP 2014008139A0 AP 2014008139 A AP2014008139 A AP 2014008139A AP 2014008139 A AP2014008139 A AP 2014008139A AP 2014008139 A0 AP2014008139 A0 AP 2014008139A0
- Authority
- AP
- ARIPO
- Prior art keywords
- histamine
- receptor ligands
- acrylamide compounds
- acrylamide
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3464CH2012 | 2012-08-23 | ||
PCT/IN2012/000796 WO2014030170A1 (en) | 2012-08-23 | 2012-12-05 | Acrylamide compounds as histamine h3 receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2014008139A0 true AP2014008139A0 (en) | 2014-12-31 |
Family
ID=54187093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2014008139A AP2014008139A0 (en) | 2012-08-23 | 2012-12-05 | Acrylamide compounds as histamine H3 receptor ligands |
Country Status (27)
Country | Link |
---|---|
US (1) | US9328092B2 (it) |
EP (1) | EP2888243B1 (it) |
JP (1) | JP5981654B2 (it) |
KR (1) | KR101707343B1 (it) |
CN (1) | CN104540812B (it) |
AP (1) | AP2014008139A0 (it) |
AU (1) | AU2012388383C1 (it) |
BR (1) | BR112015001524B1 (it) |
CA (1) | CA2878217C (it) |
CY (1) | CY1118035T1 (it) |
DK (1) | DK2888243T3 (it) |
EA (1) | EA025136B1 (it) |
ES (1) | ES2592819T3 (it) |
HK (1) | HK1204620A1 (it) |
HR (1) | HRP20161167T1 (it) |
HU (1) | HUE030901T2 (it) |
IL (1) | IL236437A (it) |
LT (1) | LT2888243T (it) |
ME (1) | ME02519B (it) |
MX (1) | MX360001B (it) |
PL (1) | PL2888243T3 (it) |
PT (1) | PT2888243T (it) |
RS (1) | RS55158B1 (it) |
SG (1) | SG11201408423XA (it) |
SI (1) | SI2888243T1 (it) |
SM (1) | SMT201600336B (it) |
WO (1) | WO2014030170A1 (it) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11313246B2 (en) * | 2016-11-30 | 2022-04-26 | General Electric Company | Gas turbine engine wash system |
WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
CN116693470A (zh) * | 2022-03-02 | 2023-09-05 | 杭州百诚医药科技股份有限公司 | 组胺h3受体抑制剂及其医药用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2526518A1 (en) * | 2003-06-12 | 2004-12-23 | Novo Nordisk A/S | 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase |
US8008301B2 (en) | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
NZ550764A (en) * | 2004-06-02 | 2009-09-25 | Hoffmann La Roche | Naphthaline derivatives useful as histamine-3-receptor ligands |
DK1761519T3 (da) * | 2004-06-21 | 2008-07-21 | Hoffmann La Roche | Indolderivater som histaminreceptorantagonister |
US7705025B2 (en) | 2004-08-23 | 2010-04-27 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
DE602006021626D1 (de) * | 2005-11-30 | 2011-06-09 | Hoffmann La Roche | 1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren |
WO2007137955A1 (en) | 2006-05-30 | 2007-12-06 | F. Hoffmann-La Roche Ag | Piperidinyl pyrimidine derivatives |
BRPI0814532A2 (pt) * | 2007-07-25 | 2015-01-27 | Hoffmann La Roche | Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação dos receptores de h3, e uso desses compostos para a preparação de medicamentos. |
US8288389B2 (en) | 2007-09-06 | 2012-10-16 | Glaxo Group Limited | Piperazine derivative having affinity for the histamine H3 receptor |
US7799816B2 (en) | 2008-02-04 | 2010-09-21 | Roche Palo Alto Llc | Imidazolinylmethyl aryl sulfonamide |
US20110046130A1 (en) | 2008-03-31 | 2011-02-24 | Evotec Ag | Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
CA2721303C (en) | 2008-05-08 | 2016-06-28 | Evotec Ag | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
SG188212A1 (en) * | 2010-09-02 | 2013-04-30 | Suven Life Sciences Ltd | Heterocyclyl compounds as histamine h3 receptor ligands |
-
2012
- 2012-12-05 HU HUE12844650A patent/HUE030901T2/en unknown
- 2012-12-05 PL PL12844650T patent/PL2888243T3/pl unknown
- 2012-12-05 US US14/419,474 patent/US9328092B2/en active Active
- 2012-12-05 DK DK12844650.7T patent/DK2888243T3/en active
- 2012-12-05 AP AP2014008139A patent/AP2014008139A0/xx unknown
- 2012-12-05 WO PCT/IN2012/000796 patent/WO2014030170A1/en active Application Filing
- 2012-12-05 AU AU2012388383A patent/AU2012388383C1/en active Active
- 2012-12-05 RS RS20160783A patent/RS55158B1/sr unknown
- 2012-12-05 CA CA2878217A patent/CA2878217C/en active Active
- 2012-12-05 PT PT128446507T patent/PT2888243T/pt unknown
- 2012-12-05 EP EP12844650.7A patent/EP2888243B1/en active Active
- 2012-12-05 SI SI201230707A patent/SI2888243T1/sl unknown
- 2012-12-05 SG SG11201408423XA patent/SG11201408423XA/en unknown
- 2012-12-05 LT LTEP12844650.7T patent/LT2888243T/lt unknown
- 2012-12-05 ME MEP-2016-190A patent/ME02519B/me unknown
- 2012-12-05 BR BR112015001524-7A patent/BR112015001524B1/pt active IP Right Grant
- 2012-12-05 MX MX2015000064A patent/MX360001B/es active IP Right Grant
- 2012-12-05 KR KR1020157001952A patent/KR101707343B1/ko active IP Right Grant
- 2012-12-05 ES ES12844650.7T patent/ES2592819T3/es active Active
- 2012-12-05 JP JP2015528009A patent/JP5981654B2/ja active Active
- 2012-12-05 EA EA201590413A patent/EA025136B1/ru unknown
- 2012-12-05 CN CN201280075253.4A patent/CN104540812B/zh active Active
-
2014
- 2014-12-24 IL IL236437A patent/IL236437A/en active IP Right Grant
-
2015
- 2015-06-02 HK HK15105257.0A patent/HK1204620A1/xx unknown
-
2016
- 2016-09-13 HR HRP20161167TT patent/HRP20161167T1/hr unknown
- 2016-09-22 CY CY20161100943T patent/CY1118035T1/el unknown
- 2016-09-23 SM SM201600336T patent/SMT201600336B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2014007810A0 (en) | Imidazopyrrolidinone compounds | |
EP2925129A4 (en) | PRO-NEUROGENIC COMPOUNDS | |
GB201209138D0 (en) | Compounds | |
GB201214750D0 (en) | Compounds | |
GB201215357D0 (en) | Compounds | |
EP2887803A4 (en) | PRO-NEUROGENIC COMPOUNDS | |
AP2015008591A0 (en) | Heterocyclic compounds | |
EP2828262A4 (en) | IMIDAZOTRIAZINONVERBINDUNGEN | |
GB201204985D0 (en) | Compounds | |
GB201204125D0 (en) | Compounds | |
HK1187613A1 (en) | Compounds as histamine h3 receptor ligands h3 | |
GB201209096D0 (en) | Compounds | |
HK1204620A1 (en) | Acrylamide compounds as histamine h3 receptor ligands h3 | |
HK1180955A1 (en) | Heterocyclyl compounds as histamine h3 receptor ligands h3 | |
GB201217310D0 (en) | Compounds | |
ZA201409244B (en) | Acrylamide compounds as histamine h3 receptor ligands | |
TH1501000921A (th) | สารประกอบอะคริลาไมด์ในฐานะลิแกนด์ของฮิสตะมีน h3 รีเซปเตอร์ | |
GB201211308D0 (en) | Compounds for use | |
GB201211086D0 (en) | Novel anti-cancer compounds | |
GB201217311D0 (en) | Compounds | |
GB201217312D0 (en) | Compounds | |
GB201217290D0 (en) | Compounds | |
GB201215284D0 (en) | Compounds | |
TH1401001203B (th) | สารประกอบเฮเทอโรเอริลในฐานะที่เป็น 5-ht4 รีเซปเตอร์ลิแกนด์ | |
GB201214250D0 (en) | Compounds |